A recent study has uncovered a surprising connection between a common supplement and Alzheimer's disease progression. The findings, published in Nature Metabolism, reveal that glucosamine, a supplement often used for joint pain relief, may actually accelerate memory loss in individuals with Alzheimer's. This research, conducted by a team at the University of Florida, analyzed medical records and conducted experiments in mice, leading to some intriguing insights.
The Study's Findings
The study's key finding is striking: individuals with Alzheimer's who took glucosamine were 25% more likely to die within five years compared to those who didn't. This discovery was even more concerning when applied to the early stages of memory loss, known as mild cognitive impairment. Those in this stage who took glucosamine were 25% more likely to progress to full-blown Alzheimer's.
The research team's experiments in mice engineered to mimic Alzheimer's symptoms provided further insight. Blocking the enzyme responsible for producing sugars like glucosamine improved dementia symptoms, while feeding glucosamine to these mice worsened memory loss. Interestingly, healthy mice showed no effect from the supplement.
Why It Matters
Glucosamine is classified as a dietary supplement by the FDA, available over the counter without a prescription. This accessibility raises questions about its potential impact on cognitive health, especially for those already experiencing memory decline.
The supplement is an amino sugar, composed of glucose and glutamine, used by the body for cell construction. While not an essential nutrient, glucosamine is taken for joint health, particularly in the knees, based on anecdotal reports.
Unraveling the Mechanism
The study's authors focused on a lesser-known aspect of Alzheimer's: hyperglycosylation. In individuals with Alzheimer's, brain cells and proteins accumulate extra sugar coatings, known as N-glycans, which can disrupt protein function and lead to memory loss and cell death.
The researchers hypothesized that glucosamine might contribute to cognitive decline by exacerbating this hyperglycosylation process, given its widespread use among Alzheimer's patients for joint health.
What's Next and Unanswered Questions
The study's findings raise important questions. While it establishes an association between glucosamine and accelerated cognitive decline, it cannot prove causation. A controlled experiment is needed to determine if glucosamine directly causes faster cognitive decline.
Additionally, the study doesn't reveal if the harmful effects of glucosamine depend on dosage, brand, or duration of use. It also remains unclear if these findings apply to other forms of dementia.
The researchers plan to address these questions by conducting clinical trials, following dementia patients who discontinue glucosamine use, and exploring other supplements with similar breakdown mechanisms in the body.
